CTI Clinical Trial and Consulting Services, a global, privately held, full-service contract research organization, is expanding its presence with the opening of a new campus near downtown Cincinnati, Ohio. The project is projected to create 70 new jobs.

The company will occupy 37,000 square feet of the Baldwin 500 Building. The space will house CTI’s new Laboratory Services Business Unit in North America, a first step in a global expansion. The business unit will provide molecular, cellular and bioanalytical testing, as well as biorepository, and kit building services for the company’s clients.

“As we continue to expand our footprint in the Tri-state, on both sides of the river, we hope to become a model for other companies,” adds Tim Schroeder, Chairman & CEO of CTI. “Our region is incredibly rich in talent, capable, educated professionals who save lives every day, skills we saw proven time and again throughout the fight against COVID-19. We hope our continued success here encourages others to consider bringing jobs to the region. Thank you to JobsOhio, REDI Cincinnati, the State of Ohio, the City of Cincinnati, Corporex, Gravity Diagnostic, and countless other companies who have helped us get to this point.”

The new campus is less than 10 minutes from both the CTI Global Headquarters and the CTI Clinical Research Center in Norwood.

To assist the project, the company will receive a Job Creation Tax Credit from the Ohio Development Services Agency and additional incentives from the City of Cincinnati. JobsOhio plans to provide assistance for the project, which will be made public after a final agreement is executed. Local incentives from the City of Cincinnati are still pending approval.

“The Cincinnati region is setting itself apart as a leader in the biohealth industry thanks to the investment from CTI and the more than 800 biohealth companies that call the region home,” said Kimm Lauterbach, REDI Cincinnati president and CEO. “CTI’s expansion into laboratory services is a testament to the region’s continued momentum in this space. Support from the City of Cincinnati, JobsOhio, and the Ohio Development Services Agency was instrumental in making this project a success.”

CTI is currently part of 40 active COVID-19 projects for diagnosis, treatment and prevention, including work on the Janssen COVID-19 vaccine. CTI, now in its third decade, is one of the 20 largest CROs in the world with associates in more than 60 countries across six continents.

“CTI is an innovative local company that will attract top talent to our urban core,” remarked Markiea L. Carter, Interim Director, Department of Community and Economic Development for the City of Cincinnati. “They have made such a significant global impact in biotech and medicine and we are excited to welcome them to their new facility.”